Helius Medical Technologies, Inc. (HSDT) Key Metrics
HSDT valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $145.8M
- Enterprise value
- $173.0M
- P/E (TTM)
- 0.0
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 12.1
- Price / book
- 1.0
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.12
HSDT key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsHSDT returns How much profit the business earns on the capital it uses.
HSDT financial health Debt, liquidity and how easily interest is covered.
HSDT efficiency & capital use Working capital cycle and where the cash goes.
HSDT valuation history
HSDT returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
HSDT debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
HSDT price vs earnings per share
HSDT key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $63.7M | — | — | — | — | — | — | — | — | — |
| Enterprise value | $56.4M | — | — | — | — | — | — | — | — | — |
| Price / sales | 10.6 | — | — | — | — | — | — | — | — | — |
| Price / book | 0.2 | — | — | — | — | — | — | — | — | — |
| EV / sales | 9.4 | — | — | — | — | — | — | — | — | — |
| Earnings yield | −64.2% | — | — | — | — | — | — | — | — | — |
| Free cash flow yield | −96.2% | — | — | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $2.89 | $502.50 | $6,029.25 | $11,512.50 | $194,625.00 | $494,812.50 | $999,993.75 | $999,993.75 | $1,000,125.00 | $1,000,125.00 |
| Per share | ||||||||||
| Revenue per share | $0.27 | — | — | — | — | — | — | — | — | — |
| Earnings per share | −$1.85 | — | — | — | — | — | — | — | — | — |
| Operating cash flow per share | −$0.75 | — | — | — | — | — | — | — | — | — |
| Free cash flow per share | −$2.78 | — | — | — | — | — | — | — | — | — |
| Cash per share | $0.33 | — | — | — | — | — | — | — | — | — |
| Book value per share | $13.65 | — | — | — | — | — | — | — | — | — |
| Tangible book value per share | $4.73 | — | — | — | — | — | — | — | — | — |
| Capex per share | $2.03 | — | — | — | — | — | — | — | — | — |
| Shares outstanding | 22.0M | — | — | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −27.1% | −688.9% | −168.6% | −145.0% | −239.7% | −291.2% | −124.7% | — | — | — |
| Return on invested capital (ROIC) | −11.4% | — | — | — | — | — | — | — | — | — |
| Return on assets (ROA) | −26.6% | −209.0% | −70.9% | −89.7% | −175.6% | −167.3% | −51.2% | −165.3% | −516.6% | −170.3% |
| Return on tangible assets | −38.1% | −331.5% | −115.4% | −82.1% | −139.4% | −268.6% | −114.8% | −102.9% | −411.6% | −170.3% |
| Financial health | ||||||||||
| Total debt | — | $12,000 | $57,000 | $110,000 | $3,000 | $91,000 | $637,000 | $13.8M | $1.0M | $4.5M |
| Cash & short-term investments | $7.3M | $1.1M | $5.2M | $14.5M | $11.0M | $3.3M | $5.5M | $25.6M | $5.6M | $2.6M |
| Net debt | −$7.3M | −$1.1M | −$5.1M | −$14.4M | −$11.0M | −$3.2M | −$4.8M | −$11.8M | −$4.6M | $1.8M |
| Debt / equity | — | 0.01 | 0.02 | 0.01 | 0.00 | 0.02 | 0.11 | 1.40 | — | — |
| Debt / assets | — | 0.00 | 0.01 | 0.01 | 0.00 | 0.01 | 0.06 | 0.49 | 0.15 | 1.11 |
| Current ratio | 10.33 | 1.58 | 3.88 | 8.40 | 4.75 | 1.93 | 1.90 | 1.50 | 0.46 | 1.73 |
| Quick ratio | 9.96 | 1.08 | 3.64 | 8.10 | 4.57 | 1.77 | 1.75 | 1.48 | 0.46 | 1.73 |
| Interest coverage | -33.3 | -817.8 | -48.4 | -18.6 | — | -55.0 | -1.7 | -13.7 | -4.4 | -198.6 |
| Working capital | $28.1M | $1.3M | $5.4M | $14.7M | $9.9M | $2.3M | $3.4M | $9.0M | −$7.7M | $1.7M |
| Invested capital | $293.6M | −$17,000 | −$2.8M | −$6.3M | $254,000 | $631,000 | $1.0M | −$2.0M | −$12.0M | $1.8M |
| Tangible asset value | $104.2M | $1.1M | $2.3M | $8.0M | $10.2M | $2.6M | $4.0M | $9.9M | −$7.5M | −$16,193 |
| Net current asset value | $28.1M | $941,000 | $2.0M | $7.6M | $9.7M | $2.0M | $2.7M | $9.0M | −$7.7M | −$16,193 |
| Graham net-net per share | $0.22 | — | — | — | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Share buybacks (net) | — | — | — | — | — | $0 | $0 | $0 | $0 | $0 |
| Capex / revenue | 744.2% | 1.0% | 4.5% | 2.2% | 10.3% | 9.5% | 18.6% | 92.1% | — | — |
| Capex / depreciation | 65.85 | 0.08 | 0.18 | 0.07 | 0.17 | 0.13 | 1.46 | 7.46 | 11.18 | 466.91 |
| Stock-based compensation / revenue | 153.7% | 485.0% | 253.0% | 286.4% | 814.6% | 382.6% | 313.6% | 1,693.5% | — | — |
| R&D / revenue | 58.4% | 703.7% | 456.8% | 541.6% | 1,147.5% | 693.2% | 538.8% | 2,079.3% | — | — |
| SG&A / revenue | 384.4% | 1,945.8% | 1,491.6% | 1,352.0% | 2,332.6% | 1,469.6% | 1,104.3% | 3,601.3% | — | — |
| Efficiency | ||||||||||
| Days sales outstanding | — | 446.4 | 277.7 | 137.7 | 168.2 | 222.0 | 103.6 | 373.8 | — | — |
| Days of inventory on hand | 807.4 | 485.4 | 327.4 | 419.8 | 529.7 | 239.9 | 198.5 | 2,425.1 | — | — |
| Days payables outstanding | 1,008.5 | 440.3 | 362.5 | 668.5 | 1,112.1 | 588.8 | 815.8 | 18,160.3 | 60,547.1 | — |
| Cash conversion cycle (days) | — | 491.6 | 242.7 | -111.0 | -414.2 | -127.0 | -513.7 | -15,361.4 | — | — |
| Receivables turnover | — | 0.82 | 1.31 | 2.65 | 2.17 | 1.64 | 3.52 | 0.98 | 0.00 | 0.00 |
| Payables turnover | 0.36 | 0.83 | 1.01 | 0.55 | 0.33 | 0.62 | 0.45 | 0.02 | 0.01 | 0.00 |
| Inventory turnover | 0.45 | 0.75 | 1.11 | 0.87 | 0.69 | 1.52 | 1.84 | 0.15 | — | — |
| Asset turnover | 0.04 | 0.09 | 0.05 | 0.05 | 0.05 | 0.08 | 0.08 | 0.03 | 0.00 | 0.00 |
| Average receivables | — | $636,000 | $490,000 | $297,000 | $240,500 | $402,000 | $424,500 | $489,500 | $551,553 | $399,106 |
| Average payables | $1.4M | $702,000 | $579,000 | $848,000 | $908,000 | $1.2M | $2.0M | $2.9M | $2.8M | $2.2M |
| Average inventory | $1.1M | $774,000 | $523,000 | $532,500 | $432,500 | $493,500 | $495,000 | $392,000 | — | — |
| Intangibles / total assets | 64.7% | 0.0% | 0.3% | 0.8% | 7.8% | 19.6% | 17.6% | 0.0% | 0.0% | 0.0% |
Computed from HSDT's annual financial statements (latest annual report filed March 31, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
HSDT valuation and financial ratios
Based on the latest twelve months, the trailing P/E is 0.0. Helius Medical Technologies earned a return on equity of −27.1% and a return on invested capital of −11.4% in fiscal 2025.
See the HSDT income statement, the HSDT chart for price history, or the HSDT stock overview for the latest quote and news.
HSDT key metrics FAQ
What is Helius Medical Technologies's P/E ratio?
Helius Medical Technologies's trailing P/E ratio is 0.0 based on the last twelve months of earnings (as of October 18, 2026). At the end of fiscal 2025 it was —.
What is Helius Medical Technologies's return on equity?
Helius Medical Technologies's return on equity (ROE) was −27.1% in fiscal 2025: net income of -$40.9 million on average shareholders' equity of $151.0 million.
What is Helius Medical Technologies's ROIC?
Helius Medical Technologies's return on invested capital was −11.4% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
What is Helius Medical Technologies's free cash flow yield?
Helius Medical Technologies generated -$61.3 million of free cash flow in fiscal 2025, a free cash flow yield of −96.2% on its market value at year-end ($63.7 million).
What is Helius Medical Technologies's current ratio?
Helius Medical Technologies's current ratio was 10.33 at the end of fiscal 2025: current assets were 10.33 times current liabilities.